Composition:
Each Bon-One® tablet contains 0.25, 0.5 or 1.0 µg of alfacalcidol.
Indications:
- Improvement of various symptoms (hypocalcemia, tetany, bone pain, bone lesions, etc.) due to abnormal vitamin D metabolism in the following conditions:
- Chronic renal failure
- Hypoparathyroidism
- Vitamin D resistant rickets and osteomalacia
- Osteoporosis
Dosage and Administration:
The dose should be adjusted with careful monitoring of the serum Ca level.
- Chronic renal failure and osteoporosis: For adults, 0.25 — 1.0 µg, as alfacalcidol, of Bon-One® tablet is generally administered orally once a day. The dose should be adjusted according to the age of the patients and the severity of symptoms.
- Hypoparathyroidism and other diseases associated with abnormal vitamin D metabolism: For adults, 1.0 — 4.0 µg, as alfacalcidol, of Bon-One® tablet is generally administered orally once a day. The dose should be adjusted according to the dieases, age of the patients, severity of symptoms, and the type of the diseases.
Dosage for children:
The general oral dose for children with osteoporosis ranges 0.01 —0.03 µg/ kg as alfacalcidol once a day, and that for the other indications ranges 0.05 — 0.1 µg/ kg as alfacalcidol once a day. The dose should be adjusted according to the diseases and the severity symptoms.